English name：Fusidic Acid
Molecular formula：C31H48O6·1/2 H2O
3、Mechanism and clinical use:
Fusidic Acid was extracted in 1962 for the first time by the Danish LEO Pharma from the fermentation broth of Fusidium coccineum. It is a narrow-spectrum, high-efficiency and anti gram-positive bacteria antibiotic widely used in foreign countries. Fusidic Acid, as a typical high efficiency antibiotic, although has been widely used in foreign countries for more than 30 years (few used in domestic clinical), still keeps relatively strong antibacterial activity and very low resistance to most staphylococcus strain, more and more receives people’s attention, and becomes new selection of anti resistant staphylococcus aureus (MRSA).
Fusidic Acid is an antibiotic, mainly used for treatment of infections incurred by all kinds of sensitive bacteria, especially by staphylococcus, such as osteomyelitis, sepsis, endocarditis; repeated infections of cystic fibrosis, pneumonia, skin and soft tissue; and infections of surgery and trauma, etc.
On Feb 2020, API Fusidic Acid was granted “written confirmation for active substance exported to EU”.
On June 2020, API Fusidic Acid was granted CEP certificate.
On Feb 2020，Obtain the GMP certificate of EU.
4、Packaging size specification
Inner package: single-layer polyethylene bag and aluminum foil bag.
Outer package: fiber drum.
Packaging size: 20 Kg/drum